Analysts Issue Forecasts for C4 Therapeutics Q2 Earnings

C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Investment analysts at Brookline Capital Management issued their Q2 2025 earnings estimates for shares of C4 Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Brookline Capital Management analyst L. Cann expects that the company will post earnings of ($0.39) per share for the quarter. The consensus estimate for C4 Therapeutics' current full-year earnings is ($1.52) per share.

Several other brokerages have also recently issued reports on CCCC. Wells Fargo & Company raised shares of C4 Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $8.00 to $12.00 in a research note on Thursday, December 19th. Stephens started coverage on shares of C4 Therapeutics in a report on Monday, November 18th. They set an "equal weight" rating and a $4.00 target price on the stock. Finally, UBS Group raised shares of C4 Therapeutics to a "hold" rating in a research report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $12.50.

C4 Therapeutics Trading Down 2.9 %

C4 Therapeutics stock traded down $0.07 during midday trading on Monday, reaching $2.36. 874,373 shares of the stock traded hands, compared to its average volume of 1,787,009. The firm has a market cap of $167.54 million, a PE ratio of -1.39 and a beta of 2.99. The company has a 50-day simple moving average of $3.39 and a two-hundred day simple moving average of $4.71. C4 Therapeutics has a 12-month low of $2.21 and a 12-month high of $11.48.

Remove Ads

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.05). The company had revenue of $5.18 million for the quarter, compared to analyst estimates of $4.43 million. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%.

Institutional Investors Weigh In On C4 Therapeutics

A number of large investors have recently modified their holdings of CCCC. Intech Investment Management LLC raised its holdings in C4 Therapeutics by 11.1% during the fourth quarter. Intech Investment Management LLC now owns 30,150 shares of the company's stock worth $109,000 after purchasing an additional 3,024 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of C4 Therapeutics by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 486,366 shares of the company's stock valued at $1,751,000 after purchasing an additional 3,437 shares during the period. Rhumbline Advisers grew its stake in C4 Therapeutics by 4.6% during the 4th quarter. Rhumbline Advisers now owns 100,015 shares of the company's stock worth $360,000 after buying an additional 4,366 shares during the last quarter. Invesco Ltd. increased its position in C4 Therapeutics by 7.2% during the fourth quarter. Invesco Ltd. now owns 69,193 shares of the company's stock worth $249,000 after buying an additional 4,647 shares during the period. Finally, Northern Trust Corp increased its position in C4 Therapeutics by 1.1% during the fourth quarter. Northern Trust Corp now owns 495,043 shares of the company's stock worth $1,782,000 after buying an additional 5,223 shares during the period. 78.81% of the stock is owned by hedge funds and other institutional investors.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.